Charles Schwab
ORMP icon

Charles Schwab’s Oramed Pharmaceuticals ORMP Stock Holding History

Charles Schwab’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Buy
+83,634
New +$333K ﹤0.01% 3277
2022
Q2 		– Sell
-83,219
Closed -$720K – 3617
2022
Q1 		$720K Buy
83,219
+17,512
+27% +$179K ﹤0.01% 2981
2021
Q4 		$939K Buy
65,707
+1,456
+2% +$30.4K ﹤0.01% 2940
2021
Q3 		$1.41M Buy
64,251
+7,609
+13% +$130K ﹤0.01% 2769
2021
Q2 		$758K Buy
+56,642
New +$648K ﹤0.01% 3024

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's ORMP Position: Q2 2026 in Review

Charles Schwab opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 83,634 shares worth $402K. The stake represents ﹤0.01% of the portfolio and ranks #3277 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ORMP as recently as Q1 2022.

Charles Schwab first reported a position in ORMP in Q2 2021 and has held it in 5 quarters since. The position peaked at $1.41M in Q3 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Charles Schwab held 83,634 shares of Oramed Pharmaceuticals worth $402K as of Q2 2026.
  • Oramed Pharmaceuticals was a new Charles Schwab position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3277 holding.
  • Charles Schwab first reported a position in Oramed Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
  • Charles Schwab's Oramed Pharmaceuticals position peaked at $1.41M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.